898 related articles for article (PubMed ID: 31382100)
1. Classical psychedelics for the treatment of depression and anxiety: A systematic review.
Muttoni S; Ardissino M; John C
J Affect Disord; 2019 Nov; 258():11-24. PubMed ID: 31382100
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
[TBL] [Abstract][Full Text] [Related]
4. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
Leger RF; Unterwald EM
J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
[TBL] [Abstract][Full Text] [Related]
5. Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
[TBL] [Abstract][Full Text] [Related]
6. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
7. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
[TBL] [Abstract][Full Text] [Related]
8. Psychedelics and Personality.
Aixalà M; Dos Santos RG; Hallak JEC; Bouso JC
ACS Chem Neurosci; 2018 Oct; 9(10):2304-2306. PubMed ID: 29863323
[TBL] [Abstract][Full Text] [Related]
9. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
Sousa TR; Rema J; Machado S; Novais F
Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
[TBL] [Abstract][Full Text] [Related]
10. Psychedelics in the treatment of unipolar mood disorders: a systematic review.
Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH
J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684
[TBL] [Abstract][Full Text] [Related]
11. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.
Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL
Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790
[TBL] [Abstract][Full Text] [Related]
12. Psychedelics for treatment resistant depression: are they game changers?
Kalfas M; Taylor RH; Tsapekos D; Young AH
Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
[TBL] [Abstract][Full Text] [Related]
13. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
[TBL] [Abstract][Full Text] [Related]
14. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.
Schimmers N; Breeksema JJ; Smith-Apeldoorn SY; Veraart J; van den Brink W; Schoevers RA
Psychopharmacology (Berl); 2022 Jan; 239(1):15-33. PubMed ID: 34812901
[TBL] [Abstract][Full Text] [Related]
15. Psychedelic drugs for psychiatric disorders.
da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Applications of Classic Hallucinogens.
Bogenschutz MP; Ross S
Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
[TBL] [Abstract][Full Text] [Related]
17. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
[No Abstract] [Full Text] [Related]
18. Cardiovascular safety of psychedelic medicine: current status and future directions.
Wsół A
Pharmacol Rep; 2023 Dec; 75(6):1362-1380. PubMed ID: 37874530
[TBL] [Abstract][Full Text] [Related]
19. Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review.
Hovmand OR; Poulsen ED; Arnfred S; Storebø OJ
J Psychopharmacol; 2023 Jul; 37(7):649-659. PubMed ID: 37403379
[TBL] [Abstract][Full Text] [Related]
20. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
